Quality Assessment of uPA and PAI-1 Tests in Breast Cancer
Author Information
Author(s): CGJ Sweep, J Geurts-Moespot, N Grebenschikov, JH de Witte, JJTM Heuvel, M Schmitt, MJ Duffy, F Janicke, MD Kramer, JA Foekens, N Brunner, G Brugal, AN Pedersen, ThJ Benraad
Primary Institution: University Hospital St. Radboud, University of Nijmegen, The Netherlands
Hypothesis
The study aims to evaluate the consistency and reliability of uPA and PAI-1 antigen determinations across different laboratories using enzyme-linked immunosorbent assay (ELISA) kits.
Conclusion
The study concludes that using the same ELISA kit and implementing external quality assurance is essential for reliable uPA and PAI-1 antigen determinations in multicenter studies.
Supporting Evidence
- High levels of uPA and PAI-1 are associated with rapid disease progression in breast cancer.
- Different ELISA kits yield varying results for uPA and PAI-1 levels.
- Using common external standards significantly reduces between-laboratory variation.
- Experienced laboratories show lower variation in results compared to non-experienced ones.
- Standardization of protein assays is crucial for multicenter studies.
Takeaway
This study checks if different labs can get the same results when testing breast cancer samples for certain proteins, and it finds that they need to use the same testing kit to do it right.
Methodology
The study involved three quality control trials assessing uPA and PAI-1 antigen analyses using different ELISA kits across multiple laboratories.
Potential Biases
Potential bias due to differences in laboratory experience and the types of ELISA kits used.
Limitations
The study highlights the variability in results due to different ELISA kits and the need for standardized procedures.
Participant Demographics
The study involved multiple laboratories across Europe, including experienced and non-experienced labs.
Want to read the original?
Access the complete publication on the publisher's website